HHS challenges Vertex Pharmaceuticals' fertility services program, alleging violations of anti-kickback laws linked to its ...

Along with its gene editing therapy Casgevy, Vertex is offering fertility preservation support for its patients—a program ...

HHS is asking the court to affirm its Office of Inspector General's finding that paying for fertility services would run ...

The S&P 500’s health care sector (NYSEARCA:XLV), holding a weightage of 12.12% in the S&P 500 index, saw a fall of 10.2% in ...

Vertex Pharmaceuticals (NASDAQ: VRTX) is a biotechnology company with a strong track record of success in developing ...

Vertex has appointed a new commercial head for ex-US activites, as the company aims to resolve its two-year row with UK health officials over the price of its cystic fibrosis drugs.

and Vertex’s chief scientific officer David Altshuler has joined the UK firm’s board. Humana to invest in digital health US health firm Humana is to expand its capability in technology ...

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Dr. Reshma Kewalramani, Chief Executive Officer and President, will present at the 43 rd Annual J.P ...

Orna Therapeutics, through its subsidiary ReNAgade Therapeutics, announced a three-year strategic research collaboration with Vertex ...

The VERTEX 80 and the VERTEX 80v vacuum FT-IR spectrometers from Bruker are based on the actively aligned UltraScan ™ interferometer, which provides PEAK spectral resolution. The precise linear ...

Vertex Pharmaceuticals (VRTX) closed the most recent trading day at $416.96, moving -1.72% from the previous trading session.